Suppr超能文献

强效 TRIM21 和补体依赖性细胞内抗病毒免疫需要 IgG3 铰链。

Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge.

机构信息

Centre for Immune Regulation (CIR) and Department of Biosciences, University of Oslo, N-0371 Oslo, Norway.

CIR and Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, P.O. Box 4956, N-0424 Oslo, Norway.

出版信息

Sci Immunol. 2022 Apr 29;7(70):eabj1640. doi: 10.1126/sciimmunol.abj1640.

Abstract

Humans have four IgG antibody subclasses that selectively or differentially engage immune effector molecules to protect against infections. Although IgG1 has been studied in detail and is the subclass of most approved antibody therapeutics, increasing evidence indicates that IgG3 is associated with enhanced protection against pathogens. Here, we report that IgG3 has superior capacity to mediate intracellular antiviral immunity compared with the other subclasses due to its uniquely extended and flexible hinge region, which facilitates improved recruitment of the cytosolic Fc receptor TRIM21, independently of Fc binding affinity. TRIM21 may also synergize with complement C1/C4-mediated lysosomal degradation via capsid inactivation. We demonstrate that this process is potentiated by IgG3 in a hinge-dependent manner. Our findings reveal differences in how the four IgG subclasses mediate intracellular immunity, knowledge that may guide IgG subclass selection and engineering of antiviral antibodies for prophylaxis and therapy.

摘要

人类有四种 IgG 抗体亚类,它们选择性或差异性地结合免疫效应分子,以抵御感染。尽管 IgG1 已经被详细研究,并且是大多数批准的抗体治疗药物的亚类,但越来越多的证据表明 IgG3 与增强对病原体的保护有关。在这里,我们报告说,由于其独特的延长和灵活的铰链区,IgG3 具有比其他亚类更好的介导细胞内抗病毒免疫的能力,这有助于改善细胞溶质 Fc 受体 TRIM21 的募集,而与 Fc 结合亲和力无关。TRIM21 也可以通过衣壳失活与补体 C1/C4 介导的溶酶体降解协同作用。我们证明,这个过程通过铰链依赖性方式被 IgG3 增强。我们的发现揭示了四种 IgG 亚类介导细胞内免疫的差异,这些知识可能指导 IgG 亚类的选择和抗病毒抗体的工程设计,以用于预防和治疗。

相似文献

4
Structural characterization of the Man5 glycoform of human IgG3 Fc.人IgG3 Fc的Man5糖型的结构表征
Mol Immunol. 2017 Dec;92:28-37. doi: 10.1016/j.molimm.2017.10.001. Epub 2017 Oct 12.

引用本文的文献

8
A guide to complement biology, pathology and therapeutic opportunity.补体生物学、病理学与治疗机会指南
Nat Rev Immunol. 2024 Feb;24(2):118-141. doi: 10.1038/s41577-023-00926-1. Epub 2023 Sep 5.

本文引用的文献

1
Target-induced clustering activates Trim-Away of pathogens and proteins.靶向诱导聚集激活了病原体和蛋白质的 Trim-Away。
Nat Struct Mol Biol. 2021 Mar;28(3):278-289. doi: 10.1038/s41594-021-00560-2. Epub 2021 Feb 25.
3
Coming together at the hinges: Therapeutic prospects of IgG3.铰链处相聚:IgG3 的治疗前景。
MAbs. 2021 Jan-Dec;13(1):1882028. doi: 10.1080/19420862.2021.1882028.
5
COVID-19 antibodies on trial.COVID-19 抗体疗法临床试验。
Nat Biotechnol. 2020 Nov;38(11):1242-1252. doi: 10.1038/s41587-020-0732-8.
8
TRIM21-From Intracellular Immunity to Therapy.TRIM21-从细胞内免疫到治疗。
Front Immunol. 2019 Aug 28;10:2049. doi: 10.3389/fimmu.2019.02049. eCollection 2019.
10
The Neonatal Fc Receptor (FcRn): A Misnomer?新生儿 Fc 受体(FcRn):一个用词不当的名称?
Front Immunol. 2019 Jul 10;10:1540. doi: 10.3389/fimmu.2019.01540. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验